# Automated Closed Cell Therapy Processing System Market

> Automated And Closed Cell Therapy Processing System Market Research Report By Cell Therapy (CAR T-Cell Therapies, TCR Gene-Edited Cell Therapies, NK Cell Therapies), By Application (Oncology, Hematology, Immunology, Neurology), By System Capability (Single-Use, Multi-Use, Closed, Semi-Closed, Open), By Scale of Production (Benchtop, Pilot Scale, Commercial Scale), By Device Type (Cell Isolators, Cell Expanders, Cell Culture Vessels, Cell Dispensers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.29%
- **2024:** $ 1.26 Billion
- **2025:** $ 1.39 Billion
- **2035:** $ 3.7 Billion
- **Key Players:** Thermo Fisher Scientific (US), Miltenyi Biotec (DE), Beckman Coulter (US), Fresenius Kabi(DE), Lonza (CH), Merck KGaA (DE), STEMCELL Technologies (CA), Cytiva (US), Becton Dickinson (US)

**Report ID:** MRFR/HC/29451-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/automated-closed-cell-therapy-processing-system-market-31223

---

## Market Summary

## Automated And Closed Cell Therapy Processing System Market Overview

As per MRFR analysis, the Automated And Closed Cell Therapy Processing System Market Size was estimated at 1.26 (USD Billion) in 2024. The Automated And Closed Cell Therapy Processing System Market Industry is expected to grow from 1.39 (USD Billion) in 2025 to 3.36 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 10.29% during the forecast period (2025 - 2034).

### Key Automated And Closed Cell Therapy Processing System Market Trends Highlighted

Key market drivers for automated and closed cell therapy processing systems include the growing prevalence of chronic diseases, advancements in cellular therapies, and increasing research and development in the field. Opportunities to be explored include the development of new and more efficient systems, the integration of artificial intelligence and machine learning, and the expansion of applications into new therapeutic areas. Recent trends in the market include the adoption of single-use technologies, the focus on reducing costs and improving efficiency, and the emphasis on patient safety and regulatory compliance.

These trends are expected to continue to shape the market in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## Automated And Closed Cell Therapy Processing System Market Drivers

### Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and genetic disorders, is a major driver of the Automated And Closed Cell Therapy Processing System Market Industry. These diseases require advanced and personalized treatment approaches, and cell therapy has emerged as a promising solution. Automated and closed cell therapy processing systems enable the efficient and scalable production of cell-based therapies, making them more accessible to patients.

### Technological Advancements

Technological advancements are another key driver of the Automated And Closed Cell Therapy Processing System Market Industry. The development of new technologies, such as gene editing and CAR T-cell therapies, has expanded the potential applications of cell therapy. Automated and closed cell therapy processing systems facilitate the implementation of these advanced technologies, ensuring the safety and consistency of the manufacturing process.

### Government Support and Funding

Government support and funding play a significant role in the growth of the Automated And Closed Cell Therapy Processing System Market Industry. Governments worldwide are recognizing the potential of cell therapy and are investing in research, development, and infrastructure. This support has helped to accelerate the development and commercialization of automated and closed cell therapy processing systems.

## Automated And Closed Cell Therapy Processing System Market Segment Insights:

### Automated And Closed Cell Therapy Processing System Market Cell Therapy Insights

The market growth is attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicine, and technological advancements in cell therapy. Cell Therapy segment is expected to witness significant growth owing to the rising adoption of CAR T-Cell Therapies, TCR Gene-Edited Cell Therapies, and NK Cell Therapies. CAR T-Cell Therapies have shown promising results in treating hematologic malignancies, and their use is expected to expand in the coming years.

TCR Gene-Edited Cell Therapies are also gaining traction due to their ability to target specific antigens and provide durable responses. NK Cell Therapies are being explored for their potential in treating various cancers and immune disorders. The Automated And Closed Cell Therapy Processing System Market is highly competitive, with several key players operating in the market. These players are focusing on developing innovative products and technologies to gain a competitive edge.

The market is also witnessing a trend towards consolidation, with larger players acquiring smaller companies to expand their portfolio and geographic reach.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### Automated And Closed Cell Therapy Processing System Market Application Insights

The Automated And Closed Cell Therapy Processing System Market is segmented by Application into Oncology, Hematology, Immunology, and Neurology. The Oncology segment is expected to hold the largest share of the market in 2023, owing to the increasing prevalence of cancer and the growing demand for personalized cancer treatments. The Hematology segment is also expected to witness significant growth due to the rising incidence of blood-related disorders and the growing adoption of cell-based therapies. The Immunology and Neurology segments are expected to grow at a steady pace, driven by the increasing demand for therapies for autoimmune diseases and neurological disorders.

### Automated And Closed Cell Therapy Processing System Market System Capability Insights

The System Capability segment of the Automated And Closed Cell Therapy Processing System Market can be categorized into Single-Use, Multi-Use, Closed, Semi-Closed, and Open systems. Among these, Single-Use systems held the largest market share in 2023, accounting for around 55% of the Automated And Closed Cell Therapy Processing System Market revenue. The increasing adoption of Single-Use systems can be attributed to their advantages, such as reduced risk of cross-contamination, improved safety, and ease of operation.

Multi-Use systems are expected to witness significant growth over the forecast period, owing to their lower cost and higher flexibility compared to Single-Use systems. Closed systems offer a sterile and controlled environment for cell therapy processing, which is expected to drive their demand in the coming years. Semi-Closed and Open systems are also expected to contribute to the growth of the Automated And Closed Cell Therapy Processing System Market, albeit at a slower pace.

### Automated And Closed Cell Therapy Processing System Market Scale of Production Insights

The Automated And Closed Cell Therapy Processing System Market is segmented by scale of production into benchtop, pilot scale, and commercial scale. The commercial scale segment is expected to hold the largest share of the market in 2023, accounting for over 50% of the Automated And Closed Cell Therapy Processing System Market revenue. This is due to the increasing demand for automated and closed cell therapy processing systems from large-scale cell therapy manufacturers.

The pilot scale segment is expected to grow at the highest CAGR during the forecast period, owing to the increasing adoption of pilot-scale systems for process development and optimization. The benchtop segment is expected to account for a small share of the market, as it is primarily used for research and development purposes.

### Automated And Closed Cell Therapy Processing System Market Device Type Insights

The Device Type segment of the Automated And Closed Cell Therapy Processing System Market is projected to witness significant growth over the forecast period, driven by the increasing demand for cell-based therapies and the need for efficient and automated cell processing systems. Within the Device Type segment, Cell Isolators are expected to account for a significant share of the market, owing to their critical role in isolating target cells from complex biological samples. Cell Expanders are also anticipated to gain traction due to their ability to expand cell populations ex vivo, which is essential for cell therapy applications.

Cell Culture Vessels and Cell Dispensers are other key components of the Device Type segment, contributing to the overall market growth. The Automated And Closed Cell Therapy Processing System Market revenue is expected to reach USD 1.2 billion by 2024, with a CAGR of 10.29% during the forecast period. Segmentation insights like these are crucial for market players to understand the specific dynamics of different segments and tailor their strategies accordingly.

### Automated And Closed Cell Therapy Processing System Market Regional Insights

North America is expected to account for the largest share of the market in 2023, and is expected to continue to dominate the market over the forecast period. This is due to the increasing adoption of automated and closed cell therapy processing systems in the region, as well as the presence of major market players in the region. Europe is expected to account for the second largest market share in 2023, and is expected to grow at a CAGR of around 10.5% over the forecast period.

This is due to the increasing demand for automated and closed cell therapy processing systems in the region, as well as the presence of major market players in the region.

Asia Pacific is expected to account for the third largest market share in 2023, and is expected to grow at a CAGR of around 11.0% over the forecast period. This is due to the increasing demand for automated and closed cell therapy processing systems in the region, as well as the presence of major market players in the region. South America and the Middle East and Africa are expected to account for the smallest market share in 2023, and are expected to grow at a CAGR of around 10.0% and 10.5%, respectively, over the forecast period.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## Automated And Closed Cell Therapy Processing System Market Key Players And Competitive Insights:

Major players in Automated And Closed Cell Therapy Processing System Market industry are consistently striving to enhance their product portfolios and expand their global presence. Leading Automated And Closed Cell Therapy Processing System Market players are actively involved in strategic collaborations, mergers, and acquisitions to gain a competitive edge. The Automated And Closed Cell Therapy Processing System Market industry is characterized by intense competition among established players, as well as emerging startups that are introducing innovative technologies and solutions.

The competitive landscape is expected to remain dynamic over the forecast period, as players continue to invest in research and development and seek opportunities for growth.

One of the leading companies in the Automated And Closed Cell Therapy Processing System Market is Terumo BCT. The company offers a comprehensive range of automated and closed cell therapy processing systems, including the Spectra Optia and Quantum systems. Terumo BCT has a strong global presence and is continuously expanding its operations through strategic partnerships and acquisitions. The company is committed to providing innovative solutions that improve the safety and efficiency of cell therapy processing.

A competitor company in the Automated And Closed Cell Therapy Processing System Market is Fresenius Kabi. The company offers a range of automated cell processing systems, including the Sepax and Cryostar systems. Fresenius Kabi has a strong focus on research and development and is constantly innovating to meet the evolving needs of the cell therapy industry. The company has a global presence and is committed to providing high-quality products and services to its customers.

### Key Companies in the Automated And Closed Cell Therapy Processing System Market Include:

## Automated Closed Cell Therapy Processing System Market Industry Developments

- **Q2 2024: Miltenyi Biotec Launches CliniMACS Prodigy® T Cell Transduction Process for Automated CAR-T Manufacturing** Miltenyi Biotec announced the launch of its CliniMACS Prodigy® T Cell Transduction Process, an automated closed system designed to streamline CAR-T cell manufacturing and improve process consistency for cell therapy developers.
- **Q1 2024: Thermo Fisher Scientific Expands Cell Therapy Manufacturing Capabilities with New Automated Platform** Thermo Fisher Scientific unveiled a new automated closed cell therapy processing system aimed at increasing scalability and reducing contamination risks in cell therapy production.
- **Q2 2024: Fujifilm Irvine Scientific Opens New Cell Culture Media Manufacturing Facility in Europe** Fujifilm Irvine Scientific opened a new manufacturing facility in Tilburg, Netherlands, to support the production of cell culture media for automated closed cell therapy processing systems.
- **Q1 2024: Lonza Announces Strategic Partnership with CellPoint to Advance Automated Cell Therapy Manufacturing** Lonza entered a strategic partnership with CellPoint to co-develop and commercialize automated closed cell therapy processing platforms for decentralized manufacturing.
- **Q2 2024: BioNTech Acquires InstaDeep to Accelerate AI-Driven Automation in Cell Therapy Manufacturing** BioNTech completed the acquisition of InstaDeep, aiming to integrate AI-driven automation into its closed cell therapy processing systems to enhance manufacturing efficiency.
- **Q1 2025: Cytiva Launches New FlexFactory Platform for Automated Cell Therapy Processing** Cytiva introduced the FlexFactory platform, a modular automated closed system designed to support scalable cell therapy manufacturing and improve process control.
- **Q2 2025: Sartorius Invests $100 Million in New Cell Therapy Automation Facility in the U.S.** Sartorius announced a $100 million investment to build a new facility in Massachusetts dedicated to automated closed cell therapy processing systems.
- **Q1 2025: Terumo BCT Receives FDA Clearance for Automated Cell Therapy Processing Device** Terumo BCT received FDA clearance for its new automated closed cell therapy processing device, enabling streamlined and compliant manufacturing for cell therapy products.
- **Q2 2024: GE HealthCare Unveils New Automated Cell Therapy Manufacturing Suite** GE HealthCare launched a new suite of automated closed cell therapy processing systems designed to support high-throughput manufacturing for clinical and commercial cell therapies.
- **Q1 2025: CellGenix Secures €30 Million Series B Funding to Expand Automated Cell Therapy Processing Solutions** CellGenix raised €30 million in Series B funding to accelerate the development and commercialization of its automated closed cell therapy processing platforms.
- **Q2 2025: BioNTech Opens New Automated Cell Therapy Manufacturing Facility in Germany** BioNTech inaugurated a new facility in Mainz, Germany, dedicated to automated closed cell therapy processing, expanding its manufacturing capacity for advanced therapies.
- **Q1 2024: ScaleReady Announces Partnership with Thermo Fisher Scientific to Advance Automated Cell Therapy Processing** ScaleReady and Thermo Fisher Scientific formed a partnership to co-develop automated closed cell therapy processing systems, aiming to improve scalability and reduce costs for cell therapy manufacturers.

## Automated And Closed Cell Therapy Processing System Market Segmentation Insights

### Automated And Closed Cell Therapy Processing System Market Cell Therapy Outlook

### Automated And Closed Cell Therapy Processing System Market Application Outlook

### Automated And Closed Cell Therapy Processing System Market System Capability Outlook

### Automated And Closed Cell Therapy Processing System Market Scale of Production Outlook

### Automated And Closed Cell Therapy Processing System Market Device Type Outlook

### Automated And Closed Cell Therapy Processing System Market Regional Outlook

## Market Drivers

### Technological Innovations

Technological advancements play a pivotal role in shaping the Automated And Closed Cell Therapy Processing System Market. Innovations such as automation, artificial intelligence, and machine learning are revolutionizing the way cell therapies are processed. These technologies enhance efficiency, reduce human error, and improve the overall quality of cell products. For instance, automated systems can streamline workflows, allowing for faster processing times and increased throughput. As a result, the market is witnessing a shift towards more sophisticated processing systems that can meet the growing demands of the healthcare sector, indicating a robust future for the Automated And Closed Cell Therapy Processing System Market.

### Rising Demand for Cell Therapies

The increasing prevalence of chronic diseases and genetic disorders drives the demand for innovative treatment options, particularly in the Automated And Closed Cell Therapy Processing System Market. As healthcare providers seek to enhance patient outcomes, the adoption of cell therapies is on the rise. According to recent data, the market for cell therapies is projected to grow significantly, with estimates suggesting a compound annual growth rate of over 20% in the coming years. This surge in demand necessitates efficient processing systems that can handle the complexities of cell therapy production, thereby propelling the growth of the Automated And Closed Cell Therapy Processing System Market.

### Regulatory Support and Frameworks

Regulatory bodies are increasingly establishing supportive frameworks for the development and commercialization of cell therapies, which significantly impacts the Automated And Closed Cell Therapy Processing System Market. These regulations aim to ensure the safety and efficacy of cell-based treatments while facilitating faster approval processes. As regulatory environments become more conducive to innovation, companies are more inclined to invest in automated processing systems that comply with these standards. This alignment between regulatory support and technological advancement is expected to drive market growth, as stakeholders seek to navigate the complexities of compliance while delivering high-quality cell therapies.

### Growing Focus on Personalized Medicine

The shift towards personalized medicine is reshaping the landscape of the Automated And Closed Cell Therapy Processing System Market. As healthcare moves away from one-size-fits-all approaches, there is a growing emphasis on tailoring treatments to individual patient needs. This trend necessitates advanced processing systems capable of handling diverse cell types and customization requirements. The ability to efficiently process and manufacture personalized therapies is becoming a competitive advantage for companies in the market. Consequently, the demand for automated and closed cell therapy processing systems is likely to increase, reflecting the broader movement towards personalized healthcare solutions.

### Increased Investment in Research and Development

Investment in research and development is a critical driver for the Automated And Closed Cell Therapy Processing System Market. Pharmaceutical companies and research institutions are allocating substantial resources to explore new cell therapies and improve existing ones. This trend is evident in the rising number of clinical trials and collaborations aimed at advancing cell therapy technologies. The financial commitment to R&D not only fosters innovation but also enhances the capabilities of automated processing systems, ensuring they can accommodate the evolving needs of the market. As a result, the industry is likely to experience sustained growth fueled by these investments.

## Future Outlook

The Automated And Closed Cell Therapy Processing System Market is projected to grow at a 10.29% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for personalized medicine.

**New opportunities:**

- Integration of AI-driven analytics for process optimization.
- 
- Development of mobile processing units for remote therapies.
- Expansion into emerging markets with tailored solutions.

By 2035, the market is expected to be robust, reflecting substantial growth and innovation.

## Segment Insights

### By Cell Therapy: CAR T-Cell Therapies (Largest) vs. TCR Gene-Edited Cell Therapies (Fastest-Growing)

The Automated and Closed Cell Therapy Processing System Market features a dynamic landscape of cell therapies. Among these, CAR T-Cell Therapies hold the largest market share, benefiting from extensive clinical validation and successful treatment outcomes in hematological malignancies. TCR Gene-Edited Cell Therapies, while not as dominant currently, are rapidly gaining traction due to innovative advancements and a growing understanding of T cell functions, promising a shift in market dynamics in the near future.

Cell Therapy: CAR T-Cell Therapies (Dominant) vs. NK Cell Therapies (Emerging)

CAR T-Cell Therapies are characterized by their proven effectiveness against certain blood cancers and their established regulatory pathways, positioning them as the dominant player in the market. In contrast, NK Cell Therapies are considered emerging entities that leverage the innate immune response to target tumors, offering a unique therapeutic approach. While still in the early stages compared to CAR T-Cell therapies, NK Cell therapies are gaining attention for their potential in solid tumors and chronic infections, attracting significant research and investment aimed at overcoming existing challenges.

### By Application: Oncology (Largest) vs. Immunology (Fastest-Growing)

The Automated And Closed Cell Therapy Processing System Market showcases a dynamic distribution among various applications, with Oncology dominating the segment. As a well-established field, Oncology commands significant attention from both practitioners and researchers, driving the demand for innovative processing systems. Following closely, Hematology and Neurology hold substantial shares, but their market presence is eclipsed by Oncology's robust growth. [Immunology](https://www.marketresearchfuture.com/reports/immunology-market-30261), while currently a smaller segment, demonstrates promising potential due to increasing immunotherapy advancements that leverage these processing systems. Growth trends indicate a strategic shift towards Immunology as the fastest-growing application in the market. This surge is fueled by groundbreaking research and clinical trials focused on immune-based therapies, positioning Immunology favorably for future growth prospects. Meanwhile, Oncology remains a cornerstone of the market, benefitting from continuous technological advancements that enhance treatment outcomes. The convergence of these trends signifies an evolving landscape within the Automated And Closed Cell Therapy Processing System Market, with a noteworthy influence of research investments and regulatory support championing the progression of both fields.

Hematology (Dominant) vs. Neurology (Emerging)

Hematology has established itself as a dominant player in the Automated And Closed Cell Therapy Processing System Market, attributed to its critical applications in blood-related disorders and innovative therapies. The segment is characterized by a comprehensive range of processing systems designed to improve cell handling and purification, significantly enhancing therapeutic efficacy. Conversely, Neurology represents an emerging segment, gaining traction due to an increased focus on neurodegenerative diseases and novel treatment modalities in the realm of cell therapy. The Neurology segment presents unique challenges and opportunities, as it requires the adaptation of processing systems to handle complex cellular needs. Together, these segments highlight the evolving demands within the market, reflecting diverse therapeutic areas that benefit significantly from advancements in automated processing solutions.

### By System Capability: Single-Use (Largest) vs. Multi-Use (Fastest-Growing)

The Automated And Closed Cell Therapy Processing System Market is increasingly dominated by the Single-Use segment, which has captured a significant portion of the market share due to its flexibility and cost-effectiveness. The adoption of Single-Use systems allows for enhanced operational efficiency and reduced risk of cross-contamination, making it a preferred choice for many manufacturers in the processing of cell-based therapeutics. Conversely, the Multi-Use systems are gaining traction, specifically with companies looking for sustainable solutions, yet they still hold a smaller share compared to Single-Use systems. Growth trends in this segment indicate a shift towards more innovative technologies, with an emphasis on market needs for automation and efficiency. Companies are investing in Multi-Use systems as they explore new therapeutic applications, leading to rapid advancements and growing acceptance within the market. Additionally, the rising demand for personalized medicine is driving the development of closed and semi-closed systems, which offer enhanced control over the processing environment and further align with stringent regulatory standards.

Closed (Dominant) vs. Semi-Closed (Emerging)

Closed systems are currently the dominant solution in the Automated And Closed Cell Therapy Processing System Market due to their ability to provide a fully enclosed processing environment, minimizing the risk of contamination. They offer greater control over the cell processing conditions, which is essential for maintaining the viability and efficacy of cell therapies. On the other hand, Semi-Closed systems, which allow for some level of operator interaction, are emerging rapidly as they strike a balance between accessibility and sterility, appealing to manufacturers seeking operational flexibility. Both systems cater to advanced therapeutic processes but differ in their operational constraints, with Closed systems being preferred for critical applications where contamination risk is paramount.

### By Scale of Production: Commercial Scale (Largest) vs. Pilot Scale (Fastest-Growing)

In the Automated And Closed Cell Therapy Processing System Market, the distribution of market share among the different scales of production reveals a strong preference towards commercial scale implementation. This segment has captured the largest share, driven by the increasing demand for scalable solutions that meet the needs of larger manufacturers. The benchtop systems, while significant, appear to cater to niche markets or smaller operations, demonstrating a limited share in the overall landscape.

Commercial Scale (Dominant) vs. Pilot Scale (Emerging)

The Commercial Scale segment stands out as the dominant force within the market, catering to organizations that require high throughput and efficiency in cell therapy processing. Characterized by advanced automation, reliability, and the ability to handle substantial volumes, commercial scale production systems have become essential for meeting the growing demands of large-scale biopharmaceutical operations. In contrast, the Pilot Scale segment emerges as a vital entry point for companies looking to validate processes before full-scale commercialization. These systems enable flexibility and experimentation, making them attractive options for research institutions and startups, thereby ensuring their rapid growth within the market.

### By Device Type: Cell Isolators (Largest) vs. Cell Expanders (Fastest-Growing)

In the Automated and Closed Cell Therapy Processing System Market, the device type segment shows a diversified distribution among various product types. Cell Isolators hold the largest market share due to their essential role in providing sterile environments for cellular processing. Meanwhile, Cell Expanders, crucial for scaling up cell production, are emerging as the fastest-growing segment, reflecting the increasing demand for larger quantities of therapeutic cells.

Cell Isolators (Dominant) vs. Cell Culture Vessels (Emerging)

Cell Isolators are pivotal in ensuring contamination-free environments for cell processing, thus dominating the Automated and Closed Cell Therapy Processing System market. Their significance is underscored by stringent regulatory requirements for cell processing, driving widespread adoption in research and clinical applications. In contrast, Cell Culture Vessels are becoming increasingly important as emerging technologies for cell growth and manipulation evolve. They are designed to optimize nutrient delivery and facilitate uniform cell distribution, making them integral to the development of advanced therapies.

## Regional Market Share Analysis

North America is expected to account for the largest share of the market in 2023, and is expected to continue to dominate the market over the forecast period. This is due to the increasing adoption of automated and closed cell therapy processing systems in the region, as well as the presence of major market players in the region. Europe is expected to account for the second largest market share in 2023, and is expected to grow at a CAGR of around 10.5% over the forecast period.

This is due to the increasing demand for automated and closed cell therapy processing systems in the region, as well as the presence of major market players in the region.

Asia Pacific is expected to account for the third largest market share in 2023, and is expected to grow at a CAGR of around 11.0% over the forecast period. This is due to the increasing demand for automated and closed cell therapy processing systems in the region, as well as the presence of major market players in the region. South America and the Middle East and Africa are expected to account for the smallest market share in 2023, and are expected to grow at a CAGR of around 10.0% and 10.5%, respectively, over the forecast period.

## Competitive Benchmarking

Major players in Automated And Closed Cell Therapy Processing System Market industry are consistently striving to enhance their product portfolios and expand their global presence. Leading Automated And Closed Cell Therapy Processing System Market players are actively involved in strategic collaborations, mergers, and acquisitions to gain a competitive edge. The Automated And Closed Cell Therapy Processing System Market industry is characterized by intense competition among established players, as well as emerging startups that are introducing innovative technologies and solutions.The competitive landscape is expected to remain dynamic over the forecast period, as players continue to invest in research and development and seek opportunities for growth.One of the leading companies in the Automated And Closed Cell Therapy Processing System Market is Terumo BCT. The company offers a comprehensive range of automated and closed cell therapy processing systems, including the Spectra Optia and Quantum systems. Terumo BCT has a strong global presence and is continuously expanding its operations through strategic partnerships and acquisitions. The company is committed to providing innovative solutions that improve the safety and efficiency of cell therapy processing.A competitor company in the Automated And Closed Cell Therapy Processing System Market is Fresenius Kabi. The company offers a range of automated cell processing systems, including the Sepax and Cryostar systems. Fresenius Kabi has a strong focus on research and development and is constantly innovating to meet the evolving needs of the cell therapy industry. The company has a global presence and is committed to providing high-quality products and services to its customers.

## Recent News & Developments

- **Q2 2024: Miltenyi Biotec Launches CliniMACS Prodigy® T Cell Transduction Process for Automated CAR-T Manufacturing** Miltenyi Biotec announced the launch of its CliniMACS Prodigy® T Cell Transduction Process, an automated closed system designed to streamline CAR-T cell manufacturing and improve process consistency for cell therapy developers.
- **Q1 2024: Thermo Fisher Scientific Expands Cell Therapy Manufacturing Capabilities with New Automated Platform** Thermo Fisher Scientific unveiled a new automated closed cell therapy processing system aimed at increasing scalability and reducing contamination risks in cell therapy production.
- **Q2 2024: Fujifilm Irvine Scientific Opens New Cell Culture Media Manufacturing Facility in Europe** Fujifilm Irvine Scientific opened a new manufacturing facility in Tilburg, Netherlands, to support the production of cell culture media for automated closed cell therapy processing systems.
- **Q1 2024: Lonza Announces Strategic Partnership with CellPoint to Advance Automated Cell Therapy Manufacturing** Lonza entered a strategic partnership with CellPoint to co-develop and commercialize automated closed cell therapy processing platforms for decentralized manufacturing.
- **Q2 2024: BioNTech Acquires InstaDeep to Accelerate AI-Driven Automation in Cell Therapy Manufacturing** BioNTech completed the acquisition of InstaDeep, aiming to integrate AI-driven automation into its closed cell therapy processing systems to enhance manufacturing efficiency.
- **Q1 2025: Cytiva Launches New FlexFactory Platform for Automated Cell Therapy Processing** Cytiva introduced the FlexFactory platform, a modular automated closed system designed to support scalable cell therapy manufacturing and improve process control.
- **Q2 2025: Sartorius Invests $100 Million in New Cell Therapy Automation Facility in the U.S.** Sartorius announced a $100 million investment to build a new facility in Massachusetts dedicated to automated closed cell therapy processing systems.
- **Q1 2025: Terumo BCT Receives FDA Clearance for Automated Cell Therapy Processing Device** Terumo BCT received FDA clearance for its new automated closed cell therapy processing device, enabling streamlined and compliant manufacturing for cell therapy products.
- **Q2 2024: GE HealthCare Unveils New Automated Cell Therapy Manufacturing Suite** GE HealthCare launched a new suite of automated closed cell therapy processing systems designed to support high-throughput manufacturing for clinical and commercial cell therapies.
- **Q1 2025: CellGenix Secures €30 Million Series B Funding to Expand Automated Cell Therapy Processing Solutions** CellGenix raised €30 million in Series B funding to accelerate the development and commercialization of its automated closed cell therapy processing platforms.
- **Q2 2025: BioNTech Opens New Automated Cell Therapy Manufacturing Facility in Germany** BioNTech inaugurated a new facility in Mainz, Germany, dedicated to automated closed cell therapy processing, expanding its manufacturing capacity for advanced therapies.
- **Q1 2024: ScaleReady Announces Partnership with Thermo Fisher Scientific to Advance Automated Cell Therapy Processing** ScaleReady and Thermo Fisher Scientific formed a partnership to co-develop automated closed cell therapy processing systems, aiming to improve scalability and reduce costs for cell therapy manufacturers.

## Automated And Closed Cell Therapy Processing System Market Segmentation Insights

### Automated And Closed Cell Therapy Processing System Market Cell Therapy Outlook

- CAR T-Cell Therapies
- TCR Gene-Edited Cell Therapies
- NK Cell Therapies

### Automated And Closed Cell Therapy Processing System Market Application Outlook

- Oncology
- Hematology
- [Immunology](../../../reports/immunology-market-30261)
- Neurology

### Automated And Closed Cell Therapy Processing System Market System Capability Outlook

- Single-Use
- Multi-Use
- Closed
- Semi-Closed
- Open

### Automated And Closed Cell Therapy Processing System Market Scale of Production Outlook

- Benchtop
- Pilot Scale
- Commercial Scale

### Automated And Closed Cell Therapy Processing System Market Device Type Outlook

- Cell Isolators
- Cell Expanders
- Cell Culture Vessels
- Cell Dispensers

### Automated And Closed Cell Therapy Processing System Market Regional Outlook

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Report Scope

| MARKET SIZE 2024 | 1.261(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.391(USD Billion) |
| MARKET SIZE 2035 | 3.705(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.29% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Miltenyi Biotec (DE), Beckman Coulter (US), Fresenius Kabi (DE), Lonza (CH), Merck KGaA (DE), STEMCELL Technologies (CA), Cytiva (US), Becton Dickinson (US) |
| Segments Covered | Cell Therapy, Application, System Capability, Scale of Production, Device Type, Regional |
| Key Market Opportunities | Advancements in automation technology enhance efficiency in the Automated And Closed Cell Therapy Processing System Market. |
| Key Market Dynamics | Technological advancements drive efficiency and precision in automated closed cell therapy processing systems, reshaping market dynamics. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Automated And Closed Cell Therapy Processing System by 2035?**
A: The market is projected to reach approximately 3.705 USD Billion by 2035.

**Q: What was the market valuation for the Automated And Closed Cell Therapy Processing System in 2024?**
A: In 2024, the market valuation stood at 1.261 USD Billion.

**Q: What is the expected CAGR for the Automated And Closed Cell Therapy Processing System market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 10.29%.

**Q: Which companies are considered key players in the Automated And Closed Cell Therapy Processing System market?**
A: Key players include Thermo Fisher Scientific, Miltenyi Biotec, Beckman Coulter, and others.

**Q: What are the projected values for CAR T-Cell Therapies in the market by 2035?**
A: The projected value for CAR T-Cell Therapies is expected to reach 1.8 USD Billion by 2035.

**Q: How does the market for Oncology applications in cell therapy compare from 2024 to 2035?**
A: The Oncology application market is projected to grow from 0.378 USD Billion in 2024 to 1.095 USD Billion by 2035.

**Q: What is the expected market size for Single-Use systems in 2035?**
A: The market size for Single-Use systems is anticipated to reach 1.134 USD Billion by 2035.

**Q: What is the projected growth for Cell Isolators in the Automated And Closed Cell Therapy Processing System market?**
A: Cell Isolators are expected to grow from 0.4 USD Billion in 2024 to 0.9 USD Billion by 2035.

**Q: What is the anticipated market value for TCR Gene-Edited Cell Therapies by 2035?**
A: The anticipated market value for TCR Gene-Edited Cell Therapies is projected to be 1.2 USD Billion by 2035.

**Q: How does the market for Commercial Scale production systems evolve from 2024 to 2035?**
A: The market for Commercial Scale production systems is expected to increase from 0.5044 USD Billion in 2024 to 1.436 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/automated-closed-cell-therapy-processing-system-market-31223*